Janux Therapeutics, Inc. (NASDAQ: JANX) reported Q3 EPS of ($0.39), $0.23 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $10 million versus the consensus estimate of $2.88 million.

For earnings history and earnings-related data on Janux Therapeutics, Inc. (JANX) click here.